BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI, few data exist on the magnitude of platelet activation, aggregation and dosing of glycoprotein (GP) IIb/IIIa receptor inhibitors. METHODS:Sixty STEMI patients were randomised to abciximab, to high-dose tirofiban or to no additional GP IIb/IIIa inhibitor treatment. Platelet activation (P-selectin expression) was measured using flow cytometry and the level of inhibition of platelet aggregation was assessed using the Plateletworks assay. Additionally, the PFA-100 with the collagen/adenosine-diphosphate cartridge (CADP) was used to compare the levels of platelet inhibition. All measurements were performed at baseline (T(0)), immediately after (T(1)), 30 minutes (T(2)), 60 minutes (T(3)) and 120 minutes (T(4)) after primary PCI. RESULTS: The level of platelet activation in both GP IIb/IIIa receptor inhibitor treated groups was significantly lower compared with the control group at all time points after primary PCI (p=0.04). Also the administration of the currently recommended dose of abciximab resulted in significantly lower levels of inhibition of aggregation compared with high-dose tirofiban (p<0.0001). In addition, the CADP closure times were significantly prolonged in both GP IIb/IIIa inhibitor treated groups compared with the control group at time points T(1) (p=0.006) and T(4) (p<0.0001). CONCLUSION: The administration of high-dose tirofiban resulted in a significantly higher inhibition of platelet aggregation compared with the currently recommended dose of abciximab. Large clinical trials are needed to assess whether this laboratory superiority of high-dose tirofiban translates into higher clinical efficacy. (Neth Heart J 2007;15:375-81.).
RCT Entities:
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI, few data exist on the magnitude of platelet activation, aggregation and dosing of glycoprotein (GP) IIb/IIIa receptor inhibitors. METHODS: Sixty STEMI patients were randomised to abciximab, to high-dose tirofiban or to no additional GP IIb/IIIa inhibitor treatment. Platelet activation (P-selectin expression) was measured using flow cytometry and the level of inhibition of platelet aggregation was assessed using the Plateletworks assay. Additionally, the PFA-100 with the collagen/adenosine-diphosphate cartridge (CADP) was used to compare the levels of platelet inhibition. All measurements were performed at baseline (T(0)), immediately after (T(1)), 30 minutes (T(2)), 60 minutes (T(3)) and 120 minutes (T(4)) after primary PCI. RESULTS: The level of platelet activation in both GP IIb/IIIa receptor inhibitor treated groups was significantly lower compared with the control group at all time points after primary PCI (p=0.04). Also the administration of the currently recommended dose of abciximab resulted in significantly lower levels of inhibition of aggregation compared with high-dose tirofiban (p<0.0001). In addition, the CADP closure times were significantly prolonged in both GP IIb/IIIa inhibitor treated groups compared with the control group at time points T(1) (p=0.006) and T(4) (p<0.0001). CONCLUSION: The administration of high-dose tirofiban resulted in a significantly higher inhibition of platelet aggregation compared with the currently recommended dose of abciximab. Large clinical trials are needed to assess whether this laboratory superiority of high-dose tirofiban translates into higher clinical efficacy. (Neth Heart J 2007;15:375-81.).
Authors: Daniel Soffer; Issam Moussa; Murat Karatepe; Kishore J Harjai; Judith Boura; Simon R Dixon; Cindy L Grines; William W O'Neill; Gary S Roubin; Jeffrey W Moses Journal: Am J Cardiol Date: 2003-04-01 Impact factor: 2.778
Authors: David J Schneider; Howard C Herrmann; Nasser Lakkis; Frank Aguirre; Ying Wan; Atul Aggarwal; Samer S Kabbani; Peter M DiBattiste Journal: Am J Cardiol Date: 2002-12-15 Impact factor: 2.778
Authors: J W van Werkum; W B M Gerritsen; J C Kelder; C M Hackeng; S M Ernst; V H M Deneer; M J Suttorp; B J W M Rensing; H W M Plokker; J M Ten Berg Journal: Neth Heart J Date: 2007 Impact factor: 2.380
Authors: G Montalescot; P Barragan; O Wittenberg; P Ecollan; S Elhadad; P Villain; J M Boulenc; M C Morice; L Maillard; M Pansiéri; R Choussat; P Pinton Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245
Authors: N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman Journal: J Am Coll Cardiol Date: 1995-12 Impact factor: 24.094
Authors: Nicolette M S K J Ernst; Harry Suryapranata; Kor Miedema; Robbert J Slingerland; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Menko-Jan de Boer; Felix Zijlstra; Arnoud W J van 't Hof Journal: J Am Coll Cardiol Date: 2004-09-15 Impact factor: 24.094
Authors: J W van Werkum; W B M Gerritsen; J C Kelder; C M Hackeng; S M Ernst; V H M Deneer; M J Suttorp; B J W M Rensing; H W M Plokker; J M Ten Berg Journal: Neth Heart J Date: 2007 Impact factor: 2.380
Authors: Peter B Berger; Judson B Williams; Vic Hasselblad; Karen Chiswell; Karen S Pieper; Robert M Califf Journal: J Interv Cardiol Date: 2013-02-05 Impact factor: 2.279